Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Coumarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.52 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.49 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.47 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 11/20 | 0.95 |
| ▸ | CA9 | Q16790 | 11/20 | 0.95 |
| ▸ | CA1 | P00915 | 7/20 | 0.95 |
| ▸ | CA3 | P07451 | 7/20 | 0.95 |
| ▸ | CA4 | P22748 | 7/20 | 0.95 |
| ▸ | CA7 | P43166 | 7/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.95 |
| ▸ | CA5A | P35218 | 6/20 | 0.95 |
| ▸ | CA6 | P23280 | 6/20 | 0.95 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.95 |
| ▸ | CA2 | P00918 | 5/20 | 0.95 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.95 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coumarin SCHEMBL6920202 | 1.00 | CA12 (0.95) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL30641021 | 1.00 | CA12 (0.95) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL5996993 | 0.98 | CA12 (0.91) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL29385611 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL28886137 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL3441294 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL6252 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL1038138 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL621751 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| Coumarin SCHEMBL28031527 | 0.96 | CA12 (0.87) | CA12CA9CA1CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101703239-A | Novel agents for preventing and treating disorders connected to impaired neurotransmission | DSM IP ASSETS BV | 2010-05-12 | — | — | CN | claimed |
| EP-1802298-B1 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS BV (NL) | 2008-12-31 | — | — | EP | claimed |
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | DSM IP ASSETS B.V. (NL) | 2007-12-20 | — | — | US | claimed |
| CN-101043886-A | Novel agents for the prevention and treatment of disorders associated with impaired neurotransmission | DSM IP ASSETS BV (NL) | 2007-09-26 | — | — | CN | claimed |
| EP-1802298-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSMIP Assets B.V. (NL) | 2007-07-04 | — | — | EP | claimed |
| WO-2006042441-A2 | NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2006-04-27 | — | — | WO | claimed |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-15 | — | — | US | disclosed |
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-03-12 | — | — | US | disclosed |
| EP-3097904-B1 | DEPIGMENTING AGENTS TO LIGHTEN THE SKIN | AFFICHEM (FR) | 2019-08-14 | — | — | EP | disclosed |
| CN-108452204-A | Aromatic oil and its application process are compounded for reducing the atomization cabin of blood pressure, plant | 南京大塘金药用与芳香植物研究所 | 2018-08-28 | — | — | CN | disclosed |
| WO-2018102554-A1 | CLEAVABLE NUCLEOTIDE ANALOGS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-07 | — | — | WO | disclosed |
| CN-103300358-A | Health care product capable of improving immunity | UNIV TIANJIN | 2013-09-18 | — | — | CN | disclosed |
| WO-2013003168-A1 | NOVEL INSECT-REPELLENT COUMARIN DERIVATIVES, SYNTHESES, AND METHODS OF USE | MERIAL LIMITED (US) | 2013-01-03 | — | — | WO | disclosed |
| US-4391088-A | String for sports rackets | UNITED STATES TENNIS GUT ASSOCIATION, INC. (US) | 1983-07-05 | — | — | US | disclosed |
| US-4273833-A | AQUEOUS SOLUTION OR DISPERSION OF A CARBOXYLATED HYDROPHILIC ACRYLIC COPOLYMER, A CROSSLINKING AGENT, A POLYALKYENEPOLYAMINE OR DERIVATIVE, AND AN ULTRAVIOLET ABSORBING AGENT | UNITED STATES TRADING INTERNATIONAL, INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4169902-A | CARBOXYLATED ACRYLIC COPOLYMER, CROSSLINKING AGENT, ULTRAVIOLET RADIATION ABSORBER | UNITED STATES TRADING INTERNATIONAL, INC. (US) | 1979-10-02 | — | — | US | disclosed |
| US-4094845-A | PLANTS, CARBOXYLATED HYDROPHILIC ACRYLIC POLYMER, CROSSLINKING AGENT AND AN ULTRAVIOLET ABSORBER | UNITED STATES TRADING INTERNATIONAL, INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4082884-A | METHOD OF REDUCING FOULING OF MARINE STRUCTURES AND COATED STRUCTURE THEREOF | UNITED STATES TRADING INTERNATIONAL, INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4049869-A | CROSSLINKING A CARBOXYLATED HYDROPHILIC ACRYLIC POLYMER | UNITED STATES TRADING INTERNATIONAL, INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-3712947-A | COMPOSITIONS CONTAINING COUMARIN ETHER SUN-SCREENING COMPOUNDS | INT FLAVORS & FRAGRANCES INC (US) | 1973-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293563-A1 | Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission | CHRNA2, CHRM1, CHRM5 | MEN1 2741/4885DRD4 141/4885ACHE 34/4885 |
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | TYMP, DUT, NT5C3B | MEN1 3514/4885DRD4 2575/4885ACHE 2571/4885 |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | TYMP, DUT, NT5C3B | MEN1 3514/4885DRD4 2575/4885ACHE 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.